Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost of (a) Wegovy and (b) Mounjaro to tackle obesity.

Wegovy is recommended for National Health Service use within a specialist weight management service. It launched in the United Kingdom in September 2023. The price for Wegovy is subject to a confidential commercial agreement between Novo Nordisk and NHS England.

Mounjaro is not yet recommended for the management of obesity in the NHS. However, it is under assessment by the National Institute for Health and Care Excellence. Their recommendation is currently due to be published in December 2024. The current list price for the maximum dosage of Mounjaro is £122 for a month’s supply. The maximum annual price of Mounjaro per patient is therefore £1,464 based on 12 months at maximum dosage. This does not include service delivery costs to the NHS.